Showing 6831-6840 of 9146 results for "".
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://practicaldermatology.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym
- Incyte Opens Applications for HS-Focused Ingenuity Awardshttps://practicaldermatology.com/news/incyte-opens-applications-for-hs-focused-ingenuity-awards/2484308/Incyte has announced the launch of the Incyte Ingenuity Awards (IIA) in Hidradenitis Suppurativa (HS), a new initiative developed in collaboration with patients, advocates, and clinicians to address challenges faced by HS patients, according to a press release from
- Analysis: Fibrotic Skin Diseases Linked to Elevated ASCVD Riskhttps://practicaldermatology.com/news/analysis-fibrotic-skin-diseases-linked-to-elevated-ascvd-risk/2484276/Patients with fibrotic skin diseases may have an elevated risk of atherosclerotic cardiovascular disease (ASCVD), according to new real-world data from the TriNetX platform. The study researchers conducted a retrospective cohort
- Lebrikizumab Maintains Efficacy With Reduced Dosing Intervalhttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-with-reduced-dosing-interval/2484255/Long-term data from a 32-week extension of the ADjoin trial suggest that lebrikizumab, an IL-13 inhibitor approved for once-monthly dosing, may maintain clinical efficacy in patients with moderate-to-severe atopic dermatitis (AD) even when administered once every 8
- BE HEARD: Bimekizumab Shows Sustained Relief in HS Symptoms Through 3 Yearshttps://practicaldermatology.com/news/be-heard-bimekizumab-shows-sustained-relief-in-hs-symptoms-through-3-years/2484274/Long-term data from the BE HEARD study showed BIMZELX® (bimekizumab-bkzx) was linked with sustained reductions in draining tunnels and clinically meaningful skin pain relief in patients with moderate-to-severe hidradenitis suppurativa (HS) through three years. <
- Tapinarof Sustains AD Remission for 75+ Days Post-Treatmenthttps://practicaldermatology.com/news/tapinarof-sustains-ad-remission-for-75-days-post-treatment/2484253/New long-term data from the ADORING 3 trial show that tapinarof cream 1% (VTAMA, Organon), a non-steroidal topical aryl hydrocarbon receptor agonist, can sustain low disease activity and pruritus in patients with atopic dermatitis (AD), including children as young
- TrUE-AD4: Opzelura Shows Rapid, Significant Efficacy in Moderate ADhttps://practicaldermatology.com/news/true-ad4-opzelura-shows-rapid-significant-efficacy-in-moderate-ad/2484225/New data from Incyte’s phase 3b TRuE-AD4 trial show that Opzelura® (ruxolitinib cream 1.5%) improved clinical symptoms of moderate atopic dermatitis (AD) in adults with limited response or intolerance to standard thearpy. The
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B
- Nemolizumab Shows Durable Patient-Reported Benefits at 100 Weeks in PNhttps://practicaldermatology.com/news/nemolizumab-shows-durable-patient-reported-benefits-at-100-weeks-in-pn/2484116/Long-term treatment with nemolizumab continues to deliver clinically meaningful improvements in itch, sleep, and quality of life for patients with prurigo nodularis (PN), according to interim results from the open-label extension (OLYMPIA-LTE) study presented by Dr
- 487-GEP Test Identifies Optimal Systemic Therapy for ADhttps://practicaldermatology.com/news/487-gep-test-identifies-optimal-systemic-therapy-for-ad/2484115/A 487-gene expression profile (487-GEP) test may help personalize systemic therapy selection for patients with atopic dermatitis (AD), according to results from a prospective, multicenter trial presented by Dr. Jonathan Silverberg et al at the 2025 Fall Clinical De